Study:
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 Mcg to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
Rationale:
n/a
Purpose:
The study is intended to show that the Sufentanil NanoTab PCA System is as effective as
morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery.
Each patient will use either the Sufentanil NanoTab PCA System or morphine IV PCA to treat
their pain for at least 48 hours and up to 72 hours after surgery while in the hospital.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Post-Operative Pain |
Drug: Sufentanil NanoTab PCA System/15 mcg
Drug: morphine IV PCA |
Phase 3 |
Verified by
AcelRx Pharmaceuticals, Inc.
April, 2012
Sponsored by: AcelRx Pharmaceuticals, Inc.
Information provided by: AcelRx Pharmaceuticals, Inc.
ClinicalTrials.gov identifier: NCT01539538
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Pamela Palmer, M.D., PhD., Study Director